Isquaemia Biotech, a company participated by Canaan Research and Investment, is investigating the neuroprotective properties of a battery of molecules for the treatment of ischemic stroke.
Isquaemia works in collaboration with prestigious researchers from the Instituto de Química Orgánica of CSIC, the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), the Instituto de Investigación Vall d’Hebron and the Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI).
Preliminary results obtained to date have demonstrated neuroprotective properties (significantly reducing neurological damage) that allow improving the effectiveness of current treatments, which are restricted to restore blood flow or reperfusion (with pharmacological fibrinolysis or mechanical recanalization).
These results have been published in renowned scientific journals in the sector. In 2019, studies that demonstrated the antioxidant and neuroprotective effects of some developing molecules by Isquaemia Biotech for the treatment of ischemic stroke were published in the Journal of Medicinal Chemistry (J. Med. Chem. 2019; 62:2184−2201) and in ACS Chemical Neuroscience Neuroscience (ACS Chem Neurosci. 2019; 10:2703-2706).